Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
Astellas Pharma has filed a lawsuit against the US government over the Inflation Reduction Act (IRA), becoming the first Japanese pharma company to challenge the constitutionality of its provisions on drug price negotiations under Medicare. This marks the third such…
To read the full story
Related Article
- Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks
January 29, 2026
- US Unveils Up to 85% Price Cuts for IRA Round-2; Astellas’ Xtandi on the List
November 27, 2025
- Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations
January 21, 2025
- Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
September 8, 2023
BUSINESS
- High-Dose Uptravi Now Available: Nippon Shinyaku
May 21, 2026
- Myelofibrosis Med Inrebic to Go on Sale June 1: Recordati Japan
May 21, 2026
- Fuji Plans July Launch for Japan’s 1st Simponi, Ranmark Biosimilars
May 21, 2026
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Takeda Hit with Massive Damages Verdict in US Amitiza Antitrust Case
May 20, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…